(Q35120861)

6 August 2017

1 reference

title

Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations (English)

1 reference

6 August 2017

0 references

1 reference

chronic heart failure

1 reference

8

Mihai Gheorghiade

1 reference

6 August 2017

Christopher M O'Connor

2

object named as

Christopher M O'Connor

1 reference

6 August 2017

Liviu Klein

1

1 reference

6 August 2017

Wendy A Gattis

3

1 reference

6 August 2017

Manuela Zampino

4

1 reference

6 August 2017

Leonardo de Luca

5

1 reference

6 August 2017

Antonio Vitarelli

6

1 reference

6 August 2017

Francesco Fedele

7

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

American Journal of Cardiology

6 August 2017

published in

1 reference

6 August 2017

volume

91

1 reference

6 August 2017

issue

9A

1 reference

6 August 2017

page(s)

18F-40F

1 reference

Epidemiology of heart failure

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Long-Term Trends in the Incidence of and Survival with Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Inotropic therapy for heart failure: an evidence-based approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Chronic heart failure in the United States: a manifestation of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Etiology and characteristics of congestive heart failure in blacks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Heart failure in African Americans: a cardiovascular engima

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Coronary artery disease in patients with heart failure and preserved systolic function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Current medical therapy for advanced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Survival after the onset of congestive heart failure in Framingham Heart Study subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Sudden death prevention in patients with advanced ventricular dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Mechanisms and models in heart failure: A combinatorial approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Pathophysiology of chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Prolonged impairment of regional contractile function after resolution of exercise-induced angina. Evidence of myocardial stunning in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

The hibernating myocardium: implications for management of congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Apoptotic cell death in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Paracrine coronary endothelial control of left ventricular function in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Myocardial endothelin. Does it play a role in myocardial failure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

The tumor necrosis factor ligand and receptor families.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Lisinopril lowers cardiac adrenergic drive and increases beta-receptor density in the failing human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effects of atrial natriuretic peptide in clinical acute renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Left ventricular shape as a determinant of functional mitral regurgitation in patients with severe heart failure secondary to either coronary artery disease or idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Relation of left ventricular chamber shape in patients with low (< or = 40%) ejection fraction to severity of functional mitral regurgitation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

The genetics of dilated cardiomyopathy--emerging clues to the puzzle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Actin mutations in dilated cardiomyopathy, a heritable form of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

ACC/AHA guidelines for the clinical application of echocardiography: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on Clinical Application of Echocardiograph

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Chronic AT1 receptor blockade and angiotensin-converting enzyme (ACE) inhibition in (CHF 146) cardiomyopathic hamsters: effects on cardiac hypertrophy and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Hemodynamic effects of captopril in patients with severe chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Enalapril: A new angiotensin-converting enzyme inhibitor in chronic heart failure: Acute and chronic hemodynamic evaluations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Long-term hemodynamic and clinical efficacy of captopril therapy in ambulatory management of severe chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

The Effect of the Angiotensin-Converting–Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Investigation of alpha1-adrenoceptor subtypes mediating vasoconstriction in rabbit cutaneous resistance arteries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Alpha 1b-adrenoceptors mediate renal tubular sodium and water reabsorption in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Influence of isoproterenol on myocardial energetics. Experimental and clinical investigations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Both beta 1- and beta 2-adrenoceptors mediate catecholamine-evoked arrhythmias in isolated human right atrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effect of carvedilol on survival in severe chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Heart Failure 99 -- the MOXCON story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Racial differences in the frequencies of cardiac beta(1)-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Beta-blockers in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Current role of beta-adrenergic blockers in the management of chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Angiotensin II type 1 receptor blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effect of prolonged nitrate therapy on left ventricular remodeling after canine acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Increased oxidative stress in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate therapy for congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Hemodynamic and volumetric effects of venodilation with nitroglycerin in chronic mitral regurgitation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Ouabain: temporal relationship between the inotropic effect and the in vitro binding to, and dissociation from, (Na + + K + )- activated ATPase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Digoxin. A neurohormonal modulator in heart failure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Myocardial Na,K-ATPase: the molecular basis for the hemodynamic effect of digoxin therapy in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Digoxin for chronic heart failure: a review of the randomized controlled trials with special attention to the PROVED (Prospective Randomized Study of Ventricular Failure and the Efficacy of Digoxin) and RADIANCE (Randomized Assessment of Digoxin on

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

The effect of digoxin on mortality and morbidity in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Digitalis Investigation Group (DIG) trial: a stimulus for further research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Association of serum digoxin concentration and outcomes in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Sex-based differences in the effect of digoxin for the treatment of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Digoxin--new perspective on an old drug.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Clinical benefits of low serum digoxin concentrations in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Pharmacology of diuretics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effect of diuresis on the performance of the failing left ventricle in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Aldosterone in Congestive Heart Failure: Analysis of Determinants and Role in Sodium Retention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Torasemide in chronic heart failure: results of the TORIC study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Development of arrhythmias in the patient with congestive heart failure: pathophysiology, prevalence and prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Ventricular arrhythmias in severe heart failure: incidence, significance, and effectiveness of antiarrhythmic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

The natural history of idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Hypercoagulability in heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Antithrombotic therapy in atrial fibrillation: a review of randomized trials with special reference to the Stroke Prevention in Atrial Fibrillation II (SPAF II) Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Magnetic resonance imaging and invasive evaluation of development of heart failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Tumor necrosis factor-alpha: a mediator of disease progression in the failing human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Endothelin-1 as a mediator in cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Plasma endothelin in chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Prognostic value of plasma endothelin-1 in patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Vasopressin: a therapeutic target in congestive heart failure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2903336-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(02)03336-2

1 reference

6 August 2017

1 reference